The modern pre-levodopa era of Parkinson's disease: Insights into motor complications from sub-Saharan Africa

Brain

Volumn 137, Issue 10, 2014, Pages 2731-2742

  Cilia, Roberto ^a   Akpalu, Albert ^b   Sarfo, Fred Stephen ^c   Cham, Momodou ^d   Amboni, Marianna ^e,f   Cereda, Emanuele ^g   Fabbri, Margherita ^h   Adjei, Patrick ^b   Akassi, John ^c   Bonetti, Alba ^a   Pezzoli, Gianni ^a  

^a PARKINSON INSTITUTE   (Italy)

^b KORLE BU TEACHING HOSPITAL   (Ghana)

^c KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^d Comboni Hospital ^*  (Ghana)

^e UNIVERSITY OF SALERNO   (Italy)

^f IDC Hermitage Capodimonte   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^h IRCCS ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA   (Italy)

Author keywords

Dyskinesias; Levodopa; Parkinson's disease; Pathophysiology

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA;

ADULT; AFRICA SOUTH OF THE SAHARA; AGED; ANALYSIS OF VARIANCE; ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE COURSE; DYSKINESIA; FEMALE; GHANA; HUMAN; ITALY; LONGITUDINAL STUDY; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; ONSET AGE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

DYSKINESIAS; LEVODOPA; PARKINSON'S DISEASE; PATHOPHYSIOLOGY;

ADULT; AFRICA SOUTH OF THE SAHARA; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DYSKINESIA, DRUG-INDUCED; FEMALE; GHANA; HUMANS; ITALY; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84908374082     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu195     Document Type: Article

References (65)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. Washington, DC: American Psychiatric Association; 2000.
3. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985; 35: 949-56.
4. Bézard E, Olanow CW, Obeso JA. Levodopa-induced dyskinesias in the absence of nigrostriatal degeneration. Mov Disord 2013; 28: 1023-4.
5. Boyce S, Rupniak NM, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 1990; 13: 448-58.
6. Carta M, Bezard E. Contribution of pre-synaptic mechanisms to LDOPA-induced dyskinesia. Neuroscience 2011; 198: 245-51.
7. Cereda E, Barichella M, Pedrolli C, Pezzoli G. Low-protein and protein redistribution diets for Parkinson's disease patients with motor fluctuations: a systematic review. Mov Disord 2010; 25: 2021-34.
8. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20: 224-30.
9. Cilia R, Akpalu A, Cham M, Bonetti A, Amboni M, Faceli E, et al. Parkinson's disease in sub Saharan Africa: step-by-step into the challenge. Neurodegen Dis Manage 2011; 1: 193-202.
10. Cilia R, Sironi F, Akpalu A, Cham M, Sarfo FS, Brambilla T, et al. Screening LRRK2 gene mutations in patients with Parkinson's disease in Ghana. J Neurol 2012; 259: 569-70.
11. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-9.
12. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonismchronic treatment with L-DOPA. N Engl J Med 1969; 280: 337-45.
13. Cotzias GC. Levodopa in the treatment of Parkinsonism. JAMA 1971; 218: 1903-8.
14. Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K. CALM-PD Investigators of the Parkinson Study GroupImpact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 2007; 22: 1317-9.
15. de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004; 127: 2747-54.
16. de la Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 2011; 69: 803-10.
17. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987; 22: 8-12.
18. Dotchin C, Jusabani A, Walker R. Three year follow up of levodopa plus carbidopa treatment in a prevalent cohort of patients with Parkinson's disease in Hai, Tanzania. J Neurol 2011; 258: 1649-56.
19. Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011; 82: 1112-8.
20. Fahn S, Calne DB. Considerations in the management of parkinsonism. Neurology 1978; 28: 5-7.
21. Fahn S, Elton RL. UPDRS Program Members. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p. 153-63, 293-304.
22. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol 1999; 56: 529-35.
23. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-508.
24. Fahn S. A new look at levodopa based on the ELLDOPA study. J Neural Transm 2006; 70 (Suppl): 419-26.
25. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 1999; 246: 1127-33.
26. Guigoni C, Dovero S, Aubert I, Li Q, Bioulac BH, Bloch B, et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci 2005; 22: 283-87.
27. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006; 63: 1756-60.
28. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
29. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The Pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 2013; 65: 171-222.
30. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
31. Hwang WJ, Calne DB, Tsui JK, de la Fuente-Fernández R. The long-term response to levodopa in dopa-responsive dystonia. Parkinsonism Relat Disord 2001; 8: 1-5.
32. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990; 40: 1529-34.
33. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008; 9: 665-77.
34. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain 2007; 130: 2123-8.
35. Kieburtz K. Therapeutic strategies to prevent motor complications in Parkinson's disease. J Neurol 2008; 255 (Suppl 4): 42-5.
36. Kipfer S, Stephan MA, Schüpbach WM, Ballinari P, Kaelin-Lang A. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia. Arch Neurol 2011; 68: 1037-9.
37. Kurlan R. "Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology 2005; 64: 923-4.
38. Linazasoro G, Van Blercom N, Bergaretxe A, Inaki FM, Laborda E, Ruiz Ortega JA. Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study. Clin Neuropharmacol 2009; 32: 326-9.
39. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18: 467-86.
40. Manson A, Stirpe P, Schrag A. Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2012; 2: 189-98.
41. Marin C, Aguilar E, Mengod G, Cortés R, Obeso JA. Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats. Eur J Neurosci 2009; 30: 823-32.
42. Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986; 43: 402-5.
43. Mena I, Cotzias GC. Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med 1975; 292: 181-4.
44. Merola A, Zibetti M, Angrisano S, Rizzi L, Ricchi V, Artusi CA, et al. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. Brain 2011; 134: 2074-84.
45. Miyawaki E, Lyons K, Pahwa R, Tröster AI, Hubble J, Smith D, et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 1997; 20: 523-30.
46. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 1999; 14: 725-30.
47. Movement Disorders Society. Regional sections, Task Force on Africa. [updated 2013 December 19]. http://www.movementdisorders.org/regional-sections/sub-saharan/courses/accra-ghana.php. (10 March 2014, date last accessed).
48. Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol 2009; 87: 1-9.
49. Nutt JG, Nygaard TG. Response to levodopa treatment in dopa-responsive dystonia. Arch Neurol 2001; 58: 905-10.
50. Olanow WC, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013; 28: 1064-71.
51. Onofrj M, Paci C, Thomas A. Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 65: 605-6.
52. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000; 284: 1931-8.
53. Poewe W, Mahlknecht P. The clinical progression of Parkinson's disease. Parkinsonism Relat Dis 2009; 15 (Suppl 4): S28-S32.
54. Pons R, Syrengelas D, Youroukos S, Orfanou I, Dinopoulos A, Cormand B, et al. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord 2013; 28: 1058-63.
55. Rascol O, Brooks DJ, Korczyn AD, DePeyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484-91.
56. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123: 2297-305.
57. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009; 132: 2947-57.
58. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008; 15: 493-6.
59. Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008; CD006564.
60. Togasaki DM, Tan L, Protell P, Di Monte DA, Quik M, Langston JW. Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol 2001; 50: 254-7.
61. Trender-Gerhard I, Sweeney MG, Schwingenschuh P, Mir P, Edwards MJ, Gerhard A, et al. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 2009; 80: 839-45.
62. Tsironis C, Marselos M, Evangelou A, Konitsiotis S. The course of dyskinesia induction by different treatment schedules of levodopa in Parkinsonian rats: is continuous dopaminergic stimulation necessary? Mov Disord 2008; 23: 950-7.
63. Williams A. MPTP parkinsonism. Br Med J (Clin Res Ed) 1984; 289: 1401-2.
64. Zappia M, Crescibene L, Arabia G, Nicoletti G, Bagalà A, Bastone L, et al. Body weight influences pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol 2002; 25: 79-82.
65. Zhang YH, Tang BS, Song CY, Xu Q, Lou MX, Liu ZH, et al. The relationship between the phenotype of Parkinson's disease and levodopainduced dyskinesia. Neurosci Lett 2013; 556: 109-12.